For the anti-cancer drug Avastin, according to the National Institute for Health and Clinical Excellence, NICE, no NHS funding in England and Wales will be there.

Despite the drug giving an extra six weeks of life as shown by the research and it being used to combat advanced bowel cancer, the funding will not be there.

Reports say that for the drug, about 6,500 people per year may be eligible.

But it was argued by the health watchdog that the drug is just too expensive at a cost of nearly £21,000 per patient.

It was earlier confirmed by NICE that the benefits of Avastin did not justify the costs in what is called`final draft guidance'.

Decision was criticized by the charity Bowel Cancer UK and has again expressed its disappointment at NICE's guidance.

And Mark Flannagan, chief executive of Beating Bowel Cancer, said, "We believe that all treatment options should be ruled in, regardless of cost, giving doctors and their patients the freedom to choose the treatments that are right for them."

But NICE chief executive Sir Andrew Dillon defended the latest draft by stating that before also expensive drug treatments have been recommended by NICE.